#1 Clinical Trials Search in Europe

Molgramostim

Molgramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), is being investigated as a potential treatment for autoimmune pulmonary alveolar proteinosis (aPAP) and other respiratory conditions. This article explores the ongoing clinical trials evaluating the safety and efficacy of inhaled molgramostim in patients with aPAP and other lung disorders.

Table of Contents

What is Molgramostim?

Molgramostim is an investigational drug that shows promise in treating several rare lung conditions. It is a type of protein called recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)[1]. This means it’s a lab-made version of a natural protein in your body that helps certain immune cells grow and function properly. Molgramostim is not yet approved for general use, but it is being studied extensively in clinical trials to determine its safety and effectiveness[2].

What Conditions Does Molgramostim Treat?

Molgramostim is primarily being studied for the treatment of several rare lung conditions:

  • Autoimmune Pulmonary Alveolar Proteinosis (aPAP): This is a rare lung disease where a substance called surfactant builds up in the air sacs (alveoli) of the lungs, making it difficult to breathe[3].
  • Non-tuberculous Mycobacterial (NTM) Infections: These are lung infections caused by bacteria other than those that cause tuberculosis[4].
  • Acute Respiratory Distress Syndrome (ARDS): This is a severe lung condition that causes fluid to build up in the air sacs, leading to breathing difficulties[5].
  • COVID-19 Pneumonia: Molgramostim is being investigated as a potential treatment for severe lung inflammation caused by COVID-19[6].

How Does Molgramostim Work?

Molgramostim works by stimulating the growth and activity of certain white blood cells in your lungs, particularly cells called macrophages. In conditions like aPAP, these cells don’t function properly, leading to a buildup of surfactant in the lungs. By activating these cells, molgramostim may help clear the excess surfactant and improve breathing[7].

In other conditions like NTM infections or COVID-19 pneumonia, molgramostim may help boost the immune response in the lungs, potentially helping to fight off infections and reduce inflammation[4][6].

How is Molgramostim Administered?

Molgramostim is typically administered as an inhaled medication. Patients use a special device called a nebulizer to turn the liquid medication into a fine mist that can be breathed directly into the lungs. The dosage and frequency of administration can vary depending on the condition being treated and the specific clinical trial protocol[1][2].

For example, in some trials for aPAP, patients inhale molgramostim once daily for several weeks or months[7]. In other trials, it may be given in cycles, such as 7 days on and 7 days off[8].

Current Clinical Trials

Molgramostim is currently being studied in several clinical trials:

  • A trial for children and teenagers (ages 6-18) with aPAP[1].
  • A long-term safety study for adults with aPAP who have completed previous trials[2].
  • A large trial comparing molgramostim to placebo in adults with aPAP[7].
  • A study in patients with NTM infections that haven’t responded to standard antibiotics[4].
  • Trials investigating molgramostim for ARDS and severe COVID-19 pneumonia[5][6].

Potential Side Effects

As with any medication, molgramostim may cause side effects. In clinical trials, researchers carefully monitor participants for any adverse reactions. Common side effects reported in trials include:

  • Cough
  • Shortness of breath
  • Chest discomfort
  • Fever
  • Headache

More serious side effects are possible but less common. It’s important to note that the full safety profile of molgramostim is still being determined through ongoing clinical trials[8].

Aspect Details
Drug Name Molgramostim (recombinant human GM-CSF)
Administration Inhaled via nebulizer
Primary Condition Studied Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Other Conditions Non-tuberculous Mycobacterial (NTM) Infections, Acute Respiratory Distress Syndrome (ARDS)
Key Outcome Measures Lung function (DLCO), exercise capacity (6MWT), quality of life (SGRQ), gas exchange (A-a gradient)
Safety Monitoring Adverse events, serious adverse events, lung toxicity, systemic effects
Potential Benefits Improved gas exchange, reduced need for whole lung lavage, enhanced quality of life
Trial Phases Phase 2 and Phase 3 studies ongoing
Patient Age Groups Adults and pediatric patients (6-18 years old in some trials)
Treatment Duration Varies by trial, ranging from 24 weeks to 48 weeks or longer

FAQ

  • What is molgramostim and how does it work? Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) that helps activate cells responsible for clearing surfactant from the lungs. In aPAP patients, it may improve oxygen transfer from the lungs to the bloodstream.
  • How is molgramostim administered in clinical trials? In most trials, molgramostim is administered as an inhaled nebulizer solution, typically using a hand-held nebulizer device. The dosage and frequency vary between studies, with some using daily administration and others using intermittent dosing schedules.
  • What are the main conditions being studied with molgramostim? The primary focus is on autoimmune pulmonary alveolar proteinosis (aPAP), but some trials are also investigating its use in non-tuberculous mycobacterial (NTM) infections and acute respiratory distress syndrome (ARDS).
  • What are the potential benefits of molgramostim treatment? Clinical trials suggest that molgramostim may improve gas exchange, increase walking distance, enhance quality of life, and reduce the need for whole lung lavage procedures in aPAP patients. It may also help clear infections in NTM patients.
  • Are there any side effects associated with molgramostim? While specific side effects vary between trials, researchers are monitoring for adverse events such as respiratory symptoms, chest pain, and potential immune reactions. The ongoing studies aim to establish the safety profile of inhaled molgramostim.

Ongoing Clinical Trials on Molgramostim

  • A study of Pseudovax, molgramostim and tislelizumab combination therapy for patients with pseudomyxoma peritonei cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Inhaled Molgramostim for Children with Autoimmune Pulmonary Alveolar Proteinosis

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on GM-CSF, Fosfomycin, and Metronidazole for Treating Pouchitis in Ulcerative Colitis Patients Post-Surgery

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of intraperitoneal fosfomycin, metronidazole and molgramostim treatment in patients with multi-quadrant peritonitis during abdominal surgery

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Intraperitoneal Treatment with Fosfomycin, Metronidazole, and Molgramostim for Patients with Multi-Quadrant Peritonitis Undergoing Abdominal Surgery

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Inhaled Molgramostim for Adults with Autoimmune Pulmonary Alveolar Proteinosis

    Not recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Ireland Italy Poland +3

Glossary

  • Autoimmune Pulmonary Alveolar Proteinosis (aPAP): A rare lung disorder where a substance called surfactant builds up in the lungs, making it difficult to breathe. It is caused by the immune system attacking certain proteins that help clear surfactant.
  • Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A protein that stimulates the production and function of white blood cells, particularly those that help clear substances from the lungs.
  • Nebulizer: A device that turns liquid medication into a fine mist that can be inhaled into the lungs.
  • Whole Lung Lavage (WLL): An invasive procedure used to treat aPAP by washing out excess surfactant from the lungs using large amounts of saline solution.
  • Diffusing Capacity of the Lung for Carbon Monoxide (DLCO): A test that measures how well oxygen moves from the lungs into the blood, often used to assess lung function in aPAP patients.
  • 6-Minute Walk Test (6MWT): A test that measures the distance a person can walk in 6 minutes, used to assess exercise capacity and lung function.
  • St. George's Respiratory Questionnaire (SGRQ): A standardized questionnaire used to measure health-related quality of life in patients with respiratory diseases.
  • Alveolar-arterial Oxygen Gradient (A-a gradient): A measure of the difference in oxygen levels between the air in the lungs and the blood, used to assess how well the lungs are transferring oxygen.
  • Non-tuberculous Mycobacterial (NTM) Infection: A group of infections caused by mycobacteria other than those that cause tuberculosis, which can affect the lungs and other parts of the body.
  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition characterized by rapid onset of widespread inflammation in the lungs, leading to difficulty breathing and low blood oxygen levels.

References

  1. https://clinicaltrials.eu/trial/study-on-inhaled-molgramostim-for-children-with-autoimmune-pulmonary-alveolar-proteinosis/
  2. https://clinicaltrials.gov/study/NCT03482752
  3. https://clinicaltrials.gov/study/NCT06546098
  4. https://clinicaltrials.gov/study/NCT03421743
  5. https://clinicaltrials.gov/study/NCT02595060
  6. https://clinicaltrials.gov/study/NCT04569877
  7. https://clinicaltrials.eu/trial/study-of-inhaled-molgramostim-for-adults-with-autoimmune-pulmonary-alveolar-proteinosis/
  8. https://clinicaltrials.gov/study/NCT02702180